Stock ACTC ADVANCED CELL TECHNOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Advanced Cell Technology, Inc. OTC Bulletin Board

Equities

ACTC

US00752K2042

End-of-day quote OTC Bulletin Board
Other stock markets
- USD - Intraday chart for Advanced Cell Technology, Inc.

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ocata Therapeutics : Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidiaries
PR
Ocata Therapeutics : Astellas Extends Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics
PR
Ocata Therapeutics : Reports the Publication of Data about the Generation of Corneal Endothelial Cells from Human Pluripotent Stem Cells
BU
Ocata Therapeutics : Hemangio-derived Mesenchymal Cells Preserve Kidney Function and Extend Lifespan in Preclinical Model of Lupus Nephritis
BU
OCATA THERAPEUTICS : Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Merger with Astellas Pharma Inc.
BU
Ocata Therapeutics : Brower Piven Commences An Investigation Into The Proposed Sale Of Ocata Therapeutics, Inc. And Encourages Investors To Contact The Firm For Additional Information
BU
Ocata Therapeutics : Astellas to Acquire Ocata Therapeutics
PR
Ocata Therapeutics : to Host Conference Call and Webcast to Provide Corporate Update for the Third Quarter of 2015
BU
Ocata Therapeutics : to Present at Ladenburg Thalmann 2015 Healthcare Conference
BU
Ocata Therapeutics : Canine Patients Treated with Ocata’s Hemangio-derived Mesenchymal Cells (HMC™) Achieve Remission in a Model of Crohn’s Disease
BU
Ocata Therapeutics : First Patient Enrolled in Ocata Therapeutics’ Phase 2 Study for Dry AMD
BU
Ocata Therapeutics : Dr. Robert Lanza, Chief Scientific Officer of Ocata Therapeutics Awarded the Honor of iPSC Industry Influencer
BU
Ocata Therapeutics : Receives SBIR Grant from the NIH’s National Eye Institute to Develop Proprietary Photoreceptor Progenitor Cell Therapy for Retinitis Pigmentosa
BU
Ocata Therapeutics : Appoints Dr. Brian Levy to its Board of Directors
BU
Ocata Therapeutics : Receives SBIR Grant from NIH to Develop Proprietary Hemangio-derived Mesenchymal Cell Therapy for Lupus Nephritis
BU
Ocata Therapeutics : Secures $10 Million in Debt Financing
BU
Ocata Therapeutics : Provides Corporate Update for the Second Quarter of 2015
BU
Ocata Therapeutics : to Host Conference Call and Webcast to Provide Corporate Update for the Second Quarter of 2015
BU
Ocata Therapeutics : Receives New U.S. Patent for Its RPE Therapy for Macular Degenerative Diseases
BU
Ocata Therapeutics : Announces New Pre-Clinical Data to be Reported at the International Congress on Systemic Lupus Erythematosus
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. ACTC Stock
  5. News Advanced Cell Technology, Inc.